CLS: FDA submission to include 1.5 T MRI guidance for the Prism system - Redeye

Redeye endorses CLS’s FDA submission to include 1.5 Tesla MRI guidance to the Prism system. As previously highlighted, a potential approval would more than double the system’s US addressable market and is a critical driver of the Prism system’s commercial success.

Länk till analysen i sin helhet: https://www.redeye.se/research/1099049/cls-fda-submission-to-include-1-5-t-mri-guidance-for-the-prism-system?utm_source=finwire&utm_medium=RSS